CSPC PHARMA (01093): GLP-1/GIP receptor biased agonist peptide long-acting injection approved for clinical trials in China.

CSPC PHARMA (01093) announced that the long-acting GLP-1/GIP receptor biased agonist peptide injection (SYH2082 injection) developed by the group has been approved by the China National Medical Products Administration for clinical trials in China. SYH2082 was also approved by the U.S. Food and Drug Administration (FDA) in February 2026 for clinical trials in the United States. SYH2082 is expected to become a leading long-acting GLP-1/GIP receptor dual biased agonist in the clinical development stage, with monthly dosing. Leveraging the group's long-acting formulation technology platform, SYH2082 can be administered monthly, improving patient compliance and convenience of use. SYH2082 selectively activates the cAMP pathway, reduces -arrestin recruitment, thereby reducing receptor internalization and desensitization, enhancing efficacy and prolonging duration of action. In addition, SYH2082 utilizes long half-life modification platform technology and long-acting formulation platform technology to achieve sustained weight loss between doses. In preclinical studies, SYH2082 demonstrated superior efficacy in long-term weight loss and maintenance compared to similar marketed products, supporting a monthly dosing regimen. In toxicology studies, SYH2082 showed good tolerability with no significant adverse reactions observed. The approved clinical indications for this trial are weight management in overweight or obese individuals with at least one weight-related comorbidity. Furthermore, SYH2082 also has the potential to improve blood sugar control in adults with type 2 diabetes, providing clinical benefits. The approval of this clinical trial is an important achievement in the group's innovation in long-acting products in the metabolic field, laying a solid foundation for the development of more innovative products in the future.